港股異動 | 中國飛鶴(6186.HK)漲超4% 年度純利同比大增89%
格隆匯3月19日丨中國飛鶴(6186.HK)現報22.45港元,漲4.18%,暫成交1億港元,最新總市值2005億港元。中國飛鶴昨晚公佈2020年度業績稱,期內,集團的總收益為185.925億元(人民幣,下同),同比增長35.5%;母公司擁有人應占年度溢利為74.369億元,同比增長89%,每股基本盈利為0.83元,擬派末期息每股0.1586港元。公吿稱,集團的毛利率由2019年的70%增加至2020年的72.5%,主要因為集團的嬰幼兒配方奶粉產品系列(在其產品中有相對較高的毛利率)於2020年的銷售佔比增加。此外,集團管理層已制定金額為350億元的2023年銷售目標及於2024年至2028年期間實現集團銷售額15%的複合年增長率的目標。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.